Nicole K. Brogden, Ph.D. - Publications

2012 Pharmaceutical Sciences University of Kentucky, Lexington, KY 

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Swaminathan SK, Strasinger C, Kelchen M, Carr J, Ye W, Wokovich A, Ghosh P, Rajagopal S, Ueda K, Fisher J, Kandimalla KK, Brogden NK. Determination of Rate and Extent of Scopolamine Release from Transderm Scōp® Transdermal Drug Delivery Systems in Healthy Human Adults. Aaps Pharmscitech. 21: 117. PMID 32300962 DOI: 10.1208/S12249-020-01658-4  0.76
2016 Quintans-Júnior LJ, Araújo AA, Brito RG, Santos PL, Quintans JS, Menezes PP, Serafini MR, Silva GF, Carvalho FM, Brogden NK, Sluka KA. β-caryophyllene, a dietary cannabinoid, complexed with β-cyclodextrin produced anti-hyperalgesic effect involving the inhibition of Fos expression in superficial dorsal horn. Life Sciences. 149: 34-41. PMID 26883973 DOI: 10.1016/J.Lfs.2016.02.049  0.72
2015 Leelakanok N, Fischer CL, Bates AM, Guthmiller JM, Johnson GK, Salem AK, Brogden KA, Brogden NK. Cytotoxicity of HBD3 for dendritic cells, normal human epidermal keratinocytes, hTERT keratinocytes, and primary oral gingival epithelial keratinocytes in cell culture conditions. Toxicology Letters. 239: 90-6. PMID 26367466 DOI: 10.1016/J.Toxlet.2015.09.006  0.72
2015 Kinn PM, Holdren GO, Westermeyer BA, Abuissa M, Fischer CL, Fairley JA, Brogden KA, Brogden NK. Age-dependent variation in cytokines, chemokines, and biologic analytes rinsed from the surface of healthy human skin. Scientific Reports. 5: 10472. PMID 26035055 DOI: 10.1038/Srep10472  0.72
2014 Kelchen MN, Holdren GO, Farley MJ, Zimmerman MB, Fairley JA, Brogden NK. Optimization of impedance spectroscopy techniques for measuring cutaneous micropore formation after microneedle treatment in an elderly population. Pharmaceutical Research. 31: 3478-86. PMID 24947437 DOI: 10.1007/S11095-014-1435-Y  0.72
2014 Ghosh P, Brogden NK, Stinchcomb AL. Fluvastatin as a micropore lifetime enhancer for sustained delivery across microneedle-treated skin. Journal of Pharmaceutical Sciences. 103: 652-60. PMID 24395718 DOI: 10.1002/Jps.23844  0.76
2013 Milewski M, Paudel KS, Brogden NK, Ghosh P, Banks SL, Hammell DC, Stinchcomb AL. Microneedle-assisted percutaneous delivery of naltrexone hydrochloride in yucatan minipig: in vitro-in vivo correlation. Molecular Pharmaceutics. 10: 3745-57. PMID 24053426 DOI: 10.1021/Mp400227E  0.76
2013 Brogden NK, Banks SL, Crofford LJ, Stinchcomb AL. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans. Pharmaceutical Research. 30: 1947-55. PMID 23761054 DOI: 10.1007/S11095-013-1036-1  0.76
2013 Ghosh P, Brogden NK, Stinchcomb AL. Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery. Molecular Pharmaceutics. 10: 2331-9. PMID 23590208 DOI: 10.1021/Mp3007083  0.76
2013 Brogden NK, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion. Journal of Pharmaceutical Sciences. 102: 1948-56. PMID 23589356 DOI: 10.1002/Jps.23544  0.76
2012 Brogden NK, Milewski M, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Diclofenac delays micropore closure following microneedle treatment in human subjects. Journal of Controlled Release : Official Journal of the Controlled Release Society. 163: 220-9. PMID 22929967 DOI: 10.1016/J.Jconrel.2012.08.015  0.76
2012 Brogden NK, Mehalick L, Fischer CL, Wertz PW, Brogden KA. The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation. Skin Pharmacology and Physiology. 25: 167-81. PMID 22538862 DOI: 10.1159/000337927  0.72
2011 Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharmaceutical Research. 28: 1211-9. PMID 21301935 DOI: 10.1007/S11095-011-0372-2  0.72
2010 Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Therapeutic Delivery. 1: 109-31. PMID 21132122 DOI: 10.4155/Tde.10.16  0.76
2010 Milewski M, Brogden NK, Stinchcomb AL. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opinion On Drug Delivery. 7: 617-29. PMID 20205604 DOI: 10.1517/17425241003663228  0.76
2010 Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs Journal of Pharmaceutical Sciences. 99: 3072-3080. PMID 20166200 DOI: 10.1002/Jps.22083  0.72
2007 Florang VR, Rees JN, Brogden NK, Anderson DG, Hurley TD, Doorn JA. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology. 28: 76-82. PMID 16956664 DOI: 10.1016/J.Neuro.2006.07.018  0.72
Show low-probability matches.